Yıl: 2023 Cilt: 63 Sayı: 1 Sayfa Aralığı: 99 - 104 Metin Dili: İngilizce DOI: 10.14744/hnhj.2021.77044 İndeks Tarihi: 28-05-2023

Anticancer Effects of Punicalagin

Öz:
Side effects of treatments such as chemotherapy, radiotherapy, and immunotherapy, which are widely used today, nega- tively affect the cancer treatment process. In particular, the need for new treatments with less side effects but with higher therapeutic power is increasing day by day due to the resistance developing in patients against antineoplastic drugs and radiation therapy. From this point of view, natural compounds of plant origin attract attention because of their bioavailabil- ity, less side effects, and most importantly, because they can be either an auxiliary or an alternative treatment to traditional cancer treatments due to their low cost. Pomegranate (Punica granatum) is a fruit that is abundant in our country, has anticancer bioactive components such as phe- nolic compounds, and has medicinal value. The pomegranate fruit peel that constitutes approximately 30% of the weight of pomegranate fruit, which is unfortunately discarded, is actually particularly rich in phenolic compounds such as Punicalagin (PN) and Ellagic acid (EA) and various minerals. There are studies revealing that PN has direct or indirect anti-oxidant, anti-tu- mor, anti-atherosclerosis, anti-inflammatory, anti-viral, anti-fungal, and anti-bacterial effects. Its positive effects on health and its non-toxic structure enable the multifunctional use of PN compound. In this review, the therapeutic use of PN phenolic compound as an anti-cancer agent is discussed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today 2008;13:161–71.
  • 2. Hanahan D, Weinberg RA, Hanahan PD. Biological hall- marks of cancer. Holland Frei Cancer Med 2017. Avail- able at: https://www.epfl.ch/labs/hanahan-lab/ wp-content/uploads/2019/02/HanahanWeinberg-HoC_Hol- land-Frei-Ch-2-2017.pdf. Accessed Jan 18, 2023.
  • 3. Harrington KJ. The biology of cancer. Cancer Biol Imag 2016;44:1–5.
  • 4. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Pro- grammed cell death pathways in cancer: A review of apop - tosis, autophagy and programmed necrosis. Cell Prolif 2012;45:487–98.
  • 5. Khazir J, Mir BA, Pilcher L, Riley DL. Role of plants in anticancer drug discovery. Phytochem Lett 2014;7:173–81.
  • 6. da Rocha AB, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol 2001;1:364–9.
  • 7. Mishra BB, Tiwari VK. Natural products: An evolving role in fu- ture drug discovery. Eur J Med Chem 2011;46:4769–807.
  • 8. Stojanović I, Šavikin K, Đedović N, Živković J, Saksida T, Momčilović M, et al. Pomegranate peel extract ameliorates autoimmunity in animal models of multiple sclerosis and type 1 diabetes. J Funct Foods 2017;35:522–30.
  • 9. Aloqbi A, Omar U, Yousr M, Grace M, Lila MA, Howell N. Antiox- idant activity of pomegranate juice and punicalagin. Nat Sci 2016;8:235–46.
  • 10. González-Gallego J, García-Mediavilla MV, Sánchez-Campos S, Tuñón MJ. Fruit polyphenols, immunity and inflammation. Br J Nutr 2010;104(Suppl 3):S15–27.
  • 11. Petti S, Scully C. Polyphenols, oral health and disease: A re- view. J Dent 2009;37:413–23.
  • 12. van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, Jenab M, Boshuizen HC, Ros MM, et al. Fruit, vegetables, and colorectal cancer risk: The European prospective investigation into can- cer and nutrition. Am J Clin Nutr 2009;89:1441–52.
  • 13. Karakaya S, El SN. Flavonoidler Ve Sağlık. J Nutr and Diet [Arti- cle in Turkish] 1997;26:54–60.
  • 14. Hollman PC, Katan MB. Dietary flavonoids: Intake, health ef- fects and bioavailability. Food Chem Toxicol 1999;37:937–42.
  • 15. Galati G, Teng S, Moridani MY, Chan TS, O'Brien PJ. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol Drug Interact 2000;17:311–49.
  • 16. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000;52:673–751.
  • 17. Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 2001;21:381–406.
  • 18. Beutler JA, Hamel E, Vlietinck AJ, Haemers A, Rajan P, Roitman JN, et al. Structure-activity requirements for flavone cytotoxi- city and binding to tubulin. J Med Chem 1998;41:2333–8.
  • 19. Kuntz S, Wenzel U, Daniel H. Comparative analysis of the ef- fects of flavonoids on proliferation, cytotoxicity, and apopto- sis in human colon cancer cell lines. Eur J Nutr 1999;38:133– 42.
  • 20. Mojzis J, Varinska L, Mojzisova G, Kostova I, Mirossay L. Antian- giogenic effects of flavonoids and chalcones. Pharmacol Res 2008;57:259–65.
  • 21. Ravishankar D, Rajora AK, Greco F, Osborn HM. Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol 2013;45:2821–31.
  • 22. Yamagata K, Yamori Y. Inhibition of endothelial dysfunction by dietary flavonoids and preventive effects against cardiovascu- lar disease. J Cardiovasc Pharmacol 2020;75:1–9.
  • 23. Yao LH, Jiang YM, Shi J, Tomás-Barberán FA, Datta N, Singanu- song R, et al. Flavonoids in food and their health benefits. Plant Foods Hum Nutr 2004;59:113–22.
  • 24. Moe TT, Mon ZCS, Shwe HH, Myint AA. Characterization and application of natural dye extracted from rinds of pomegran- ate (Punica granatum L). IEEE-SEM 2019;7:7–12.
  • 25. Kaur C, Pal RK, Kar A, Gadi C, Sen S, Kumar P, et al. Character- ization of antioxidants and hypoglycemic potential of pome- granate grown in India: A preliminary investigation. J Food Biochem 2004;38:397–406.
  • 26. Ismail T, Sestili P, Akhtar S. Pomegranate peel and fruit extracts: A review of potential anti-inflammatory and anti-infec- tive effects. J Ethnopharmacol 2012;143:397–405.
  • 27. Karaaslan M, Yilmaz FM, Cesur O, Vardin H, Ikinci A, Dalgiç AC. Drying kinetics and thermal degradation of phenolic com- pounds and anthocyanins in pomegranate arils dried under vacuum conditions. J Food Sci Technol 2014;49:595–605.
  • 28. Baradaran Rahimi V, Ghadiri M, Ramezani M, Askari VR. Antiin- flammatory and anti-cancer activities of pomegranate and its constituent, ellagic acid: Evidence from cellular, animal, and clinical studies. Phytother Res 2020;34:685–720.
  • 29. Cam M. Basincli solvent ekstraksiyonu ile nar kabuğu ve çekirdeğinin antioksidan bileşiklerinin su ile ekstraksiyonu. Master Thesis. Kayseri: Erciyes University; 2009.
  • 30. Shirode AB, Bharali DJ, Nallanthighal S, Coon JK, Mousa SA, Reliene R. Nanoencapsulation of pomegranate bioac - tive compounds for breast cancer chemoprevention. Int J Nanomedicine 2015;10:475–84.
  • 31. Amri Z, Ghorbel A, Turki M, Akrout FM, Ayadi F, Elfeki A, et al. Effect of pomegranate extracts on brain antioxidant mark- ers and cholinesterase activity in high fat-high fructose diet induced obesity in rat model. BMC Complement Altern Med 2017;17:339.
  • 32. Lin LT, Chen TY, Lin SC, Chung CY, Lin TC, Wang GH, et al. Broad- spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol 2013;13:187.
  • 33. Anibal PC, Peixoto IT, Foglio MA, Höfling JF. Antifungal activity of the ethanolic extracts of Punica granatum L. and evalua- tion of the morphological and structural modifications of its compounds upon the cells of Candida spp. Braz J Microbiol 2013;44:839–48.
  • 34. Yao X, Cheng X, Zhang L, Yu H, Bao J, Guan H, et al. Punicalagin from pomegranate promotes human papillary thyroid carci- noma BCPAP cell death by triggering ATM-mediated DNA damage response. Nutr Res 2017;47:63–71.
  • 35. Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006;54:980–5.
  • 36. Tang JM, Min J, Li BS, Hong SS, Liu C, Hu M, et al. Therapeutic effects of punicalagin against ovarian carcinoma cells in as- sociation with β-Catenin signaling inhibition. Int J Gynecol Cancer 2016;26:1557–63.
  • 37. Tang J, Li B, Hong S, Liu C, Min J, Hu M, et al. Punicalagin sup- presses the proliferation and invasion of cervical cancer cells through inhibition of the β-catenin pathway. Mol Med Rep 2017;16:1439–44.
  • 38. Zhang L, Chinnathambi A, Alharbi SA, Veeraraghavan VP, Mohan SK, Zhang G. Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway. Saudi J Biol Sci 2020;27:1100–6.
  • 39. Cerdá B, Cerón JJ, Tomás-Barberán FA, Espín JC. Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem 2003;51:3493–501.
  • 40. Berköz M, Krośniak M. Punicalagin induces apoptosis in A549 cell line through mitochondria-mediated pathway. Gen Phys- iol Biophys 2020;39:557–67.
  • 41. Pan L, Duan Y, Ma F, Lou L. Punicalagin inhibits the viability, migration, invasion, and EMT by regulating GOLPH3 in breast cancer cells. J Recept Signal Transduct Res 2020;40:173–80.
  • 42. Cheng X, Gao Y, Yao X, Yu H, Bao J, Guan H, et al. Punicala- gin induces apoptosis-independent autophagic cell death in human papillary thyroid carcinoma BCPAP cells. RSC Adv 2016;6:68485–93.
  • 43. Luo J, Long Y, Ren G, Zhang Y, Chen J, Huang R, et al. Puni- calagin reversed the hepatic injury of tetrachloromethane by antioxidation and enhancement of autophagy. J Med Food 2019;22:1271–9.
  • 44. Wang SG, Huang MH, Li JH, Lai FI, Lee HM, Hsu YN. Punicala- gin induces apoptotic and autophagic cell death in human U87MG glioma cells. Acta Pharmacol Sin 2013;34:1411–9.
  • 45. Huang T, Zhang X, Wang H. Punicalagin inhibited proliferation, invasion and angiogenesis of osteosarcoma through suppres- sion of NF κB signaling. Mol Med Rep 2020;22:2386–94.
  • 46. Ganesan T, Sinniah A, Chik Z, Alshawsh MA. Punicalagin regu- lates Apoptosis-Autophagy switch via modulation of annexin A1 in colorectal cancer. Nutrients 2020;12:2430.
APA KILIT A, Aydemir E (2023). Anticancer Effects of Punicalagin. , 99 - 104. 10.14744/hnhj.2021.77044
Chicago KILIT A. CANSU,Aydemir Esra Anticancer Effects of Punicalagin. (2023): 99 - 104. 10.14744/hnhj.2021.77044
MLA KILIT A. CANSU,Aydemir Esra Anticancer Effects of Punicalagin. , 2023, ss.99 - 104. 10.14744/hnhj.2021.77044
AMA KILIT A,Aydemir E Anticancer Effects of Punicalagin. . 2023; 99 - 104. 10.14744/hnhj.2021.77044
Vancouver KILIT A,Aydemir E Anticancer Effects of Punicalagin. . 2023; 99 - 104. 10.14744/hnhj.2021.77044
IEEE KILIT A,Aydemir E "Anticancer Effects of Punicalagin." , ss.99 - 104, 2023. 10.14744/hnhj.2021.77044
ISNAD KILIT, A. CANSU - Aydemir, Esra. "Anticancer Effects of Punicalagin". (2023), 99-104. https://doi.org/10.14744/hnhj.2021.77044
APA KILIT A, Aydemir E (2023). Anticancer Effects of Punicalagin. Haydarpaşa Numune Medical Journal, 63(1), 99 - 104. 10.14744/hnhj.2021.77044
Chicago KILIT A. CANSU,Aydemir Esra Anticancer Effects of Punicalagin. Haydarpaşa Numune Medical Journal 63, no.1 (2023): 99 - 104. 10.14744/hnhj.2021.77044
MLA KILIT A. CANSU,Aydemir Esra Anticancer Effects of Punicalagin. Haydarpaşa Numune Medical Journal, vol.63, no.1, 2023, ss.99 - 104. 10.14744/hnhj.2021.77044
AMA KILIT A,Aydemir E Anticancer Effects of Punicalagin. Haydarpaşa Numune Medical Journal. 2023; 63(1): 99 - 104. 10.14744/hnhj.2021.77044
Vancouver KILIT A,Aydemir E Anticancer Effects of Punicalagin. Haydarpaşa Numune Medical Journal. 2023; 63(1): 99 - 104. 10.14744/hnhj.2021.77044
IEEE KILIT A,Aydemir E "Anticancer Effects of Punicalagin." Haydarpaşa Numune Medical Journal, 63, ss.99 - 104, 2023. 10.14744/hnhj.2021.77044
ISNAD KILIT, A. CANSU - Aydemir, Esra. "Anticancer Effects of Punicalagin". Haydarpaşa Numune Medical Journal 63/1 (2023), 99-104. https://doi.org/10.14744/hnhj.2021.77044